ZYUS Life Sciences Corporation (ZLSCF)
| Market Cap | 31.42M -13.2% |
| Revenue (ttm) | 263.36K -22.6% |
| Net Income | -13.70M |
| EPS | -0.17 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,420 |
| Open | 0.4267 |
| Previous Close | 0.6444 |
| Day's Range | 0.4267 - 0.6000 |
| 52-Week Range | n/a |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 26, 2026 |
About ZYUS Life Sciences
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Sas... [Read more]
Financial Performance
In 2025, ZYUS Life Sciences's revenue was 405,000, a decrease of -15.80% compared to the previous year's 481,000. Losses were -21.73 million, -35.72% less than in 2024.
Financial numbers in CAD Financial StatementsNews
ZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent
Issuance of U.S. patent supports ongoing clinical research in chronic and neuropathic pain SASKATOON, SK, May 5, 2026 /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clin...
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the "Company") (TSXV...
ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
Early Data Suggests a Trend Toward Improvement in Pain Efficacy SASKATOON, SK, Jan. 8, 2026 /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences c...
ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial
Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules SASKATOON, SK , Aug. 26, 2025 /PRNewswire/ - ZYUS Life Sciences Corporation (the "...
ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #BiotechLeadership--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commer...
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Mr. Brent H. Zettl (the “acquiror”), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (“ZYUS”) provides updates to his hol...
ZYUS Life Sciences Announces Closing of Unit Offering
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel ...
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel ...
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #Biotech--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercializatio...
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #Biotech--ZYUS Life Sciences Corporation (the “Company” and/or “ZYUS”) (TSX-V: ZYUS), a clinical stage life sciences company focused on the development and c...
Early Warning News Release Regarding the Issuance of Securities of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--On April 14, 2025, Mr. Wayne Brownlee (the "Acquiror"), who serves as a director of ZYUS Life Sciences Corporation (the “Company”) acquired control and direct...
ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel...
ZYUS Life Sciences Corporation Announces Close of Unsecured Loan and Amendment to Prior Unsecured Loans
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel...
ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan and Amendment of Existing Shareholder Promissory Note
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #Biotech--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercializati...
ZYUS Life Sciences Corporation Announces Unsecured Loan
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel...
ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel...
ZYUS Life Sciences Announces Closing of Private Placement
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel...
ZYUS Life Sciences Receives No Objection Letter from Health Canada for Proof-of-Concept Trial
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #CancerPainManagement--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and co...
ZYUS Life Sciences Receives Cannabis Drug License from Health Canada
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #Biotech--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercializati...
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Insert as subheadline: NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES The updated release reads: ZYUS LIFE SCIENCES ...
ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSXV: ZYUS) is pleased to announce that Brent Zettl, President and CEO of ZYUS, will present and hos...
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #HealthcareInnovation--ZYUS Life Sciences Corp receives U.S. Patent No. 11,963,943, entitled FORMULATION FOR PAIN MANAGEMENT.
Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate
OTTAWA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions ha...
ZYUS Life Sciences Corporation Announces Issuance of Shares for Debt Settlement
TORONTO--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) is pleased to announce that it has entered into a debt exchange agreement to settle a certain outstanding promissory note in th...
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #Phase2--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and globa...